로딩 중…
StockDiggingStockDigging

위더스제약

330350· KOSDAQ
₩8,860+13.59%
2026-06-19

Price Chart

위더스제약+12.87%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap116.95B KRW
Revenue108.89B KRW
Net Income-120.3M KRW
Total Assets142.60B KRW
Net Assets101.98B KRW
Employees218
Value
P/B1.15x
P/S1.07x
FCF Yield4.69%
Profitability
ROE-0.12%
ROA-0.08%
Op. Margin-0.42%
Revenue Growth9.50%
Earnings Growth141.19%
Financial Health
Debt Ratio139.83%
Total Debt20.75B KRW
FCF5.48B KRW
Cash19.20B KRW
Current Ratio2.00x
Dividend
Div. Yield1.28%
Div. Growth0.00%
Performance
1Y Return12.87%
1M Return19.73%
From 52W High-25.86%
1Y MDD-46.65%
Trading
Volume7,554,707 shares
Foreign Own.3.69%
Per Share
EPS552 KRW
BPS7,726 KRW

Company Info

CEO 성대영
Employees 218
Founded 2004
HQ 서울특별시 서초구, KR

Withus Pharmaceutical, headquartered in Seocho-gu, Seoul, was established in 2004 and listed on KOSDAQ in 2020, with its primary business being the production and sale of specialized medicines. The company demonstrates strengths in cardiovascular drugs, operates cephalosporin antibiotic production facilities, and engages in Contract Manufacturing Organization (CMO) services. To expand its market share in aging population and chronic disease markets, Withus Pharmaceutical is strengthening its product lineup and pharmaceutical pipeline. It is also enhancing capabilities by securing manufacturing technologies through strategic collaborations.